Anti-CD47 antibodies that block the interaction of CD47 with its ligand SIRPα, expressed on macrophages, have shown promising activity in preclinical cancer models by triggering cancer cell phagocytosis and enhancing adaptive immune responses against the cancer cells. Here, SIRPA is linked to cancer.